Skip to content

Establishment of a prognostic model and development of a detection kit for refractory cardiac arrest treated with ECPR

Establishment of a prognostic model and development of a detection kit for refractory cardiac arrest treated with ECPR

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121139
Enrollment
Unknown
Registered
2026-03-26
Start date
2026-04-05
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory cardiac arrest

Interventions

ECPR group with death vs. ECPR group with survival:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 - 70 years old (the age limit can be relaxed if the patient has good organ function and a good prognosis of neurological function after evaluation); 2. When cardiac arrest occurs, there is a witness, and a bystander performs traditional cardiopulmonary resuscitation, with the time interval from the occurrence of cardiac arrest to the start of traditional cardiopulmonary resuscitation not exceeding 5 minutes; 3. The causes of cardiac arrest include reversible etiologies such as cardiogenic causes, pulmonary embolism, severe hypothermia, drug poisoning, trauma, and acute respiratory distress syndrome. 4. Traditional cardiopulmonary resuscitation is performed for 20 minutes without the recovery of spontaneous circulation, with hemodynamic instability, or with the recovery of spontaneous circulation but the inability to maintain a spontaneous heart rhythm.

Exclusion criteria

Exclusion criteria: 1. Infectious diseases such as hepatitis B, hepatitis C, AIDS, syphilis, etc.; 2. Suffering from hematological system diseases, such as: hematological malignancies, aplastic anemia, idiopathic thrombocytopenia, etc. 3. In addition to the blood system, suffering from malignant tumors of other systems; 4. Patients who have received a large amount of plasma or platelets during hospitalization or recently.

Design outcomes

Primary

MeasureTime frame
28-day mortality;Molecular marker;

Countries

China

Contacts

Public ContactRui Gong

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

gongruiicu@126.com+86 27 85726375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026